Form 4: BioCryst Director Steven Frank Acquires Shares
Insider Transaction Report (Form 4)
BioCryst Pharmaceuticals Director Steven Frank acquired 1,353 shares of common stock at $8.31 per share as part of his board retainer.
Summary
- Steven Frank, a Director at BioCryst Pharmaceuticals Inc. (BCRX), acquired 1,353 shares of common stock.
- The transaction occurred on August 29, 2025, with shares priced at $8.31 each.
- The shares were issued to Mr. Frank in lieu of 100% of his quarterly cash Board Member retainer, totaling $11,250.
- Following this transaction, Steven Frank beneficially owns a total of 16,052 shares of BioCryst common stock.
Sentiment
Score: 7
Explanation: The acquisition of shares by a director, even as compensation, is a positive signal of confidence and alignment of interests, though not as strong as an open market purchase.
Positives
- A director increasing their stake in the company, even through compensation, signals confidence in the company's future prospects.
- Receiving stock in lieu of cash for board compensation aligns the director's financial interests more closely with those of shareholders.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing.
Industry Context
Insider transactions, such as directors acquiring shares, are generally viewed by the market as a positive indicator of management's belief in the company's value and future performance within the pharmaceutical industry.
Related Party Transactions
- The transaction involves a director (Steven Frank) receiving company common stock as compensation for his board retainer, which constitutes a related party transaction.
Stakeholder Impact
- Shareholders may view this transaction positively as it indicates increased alignment between the director's financial interests and the company's performance.
Key Dates
| Date | Description |
|---|---|
| 08/29/2025 | Date of transaction where Steven Frank acquired 1,353 shares of common stock. |
| 09/03/2025 | Date the Form 4 was signed by Alane P. Barnes, by power of attorney. |
Recommendation
holdThe director's decision to accept stock in lieu of cash for compensation suggests confidence in BioCryst's long-term prospects and aligns their interests with shareholders. While not an open market purchase, it's a positive signal that supports holding the stock, indicating insider belief in future value.
Keywords
BioCryst Pharmaceuticals, BCRX, Steven Frank, Insider Trading, Form 4, Director Compensation, Stock Acquisition, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.